Braveheart Bio, Inc. (NASDAQ:BRVE – Get Free Report) Director David Malek purchased 4,166 shares of the stock in a transaction dated Friday, August 7th. Braveheart Bio Stock PerformanceShares of BRVE stock traded up $0.20 on Friday, reaching $30.00. Braveheart Bio, Inc. has a 1 year low of $28.47 and a 1 year high of $32.00. Get Braveheart Bio alerts:Braveheart Bio Company Profile(Get Free Report)Featured ArticlesWe are a clinical?stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.